Alpha 2.0
Login Register
» Articles » PMID: 17485522

Interleukin-12: a Master Regulator

Overview
Journal J Exp Med
Specialties Allergy & Immunology
General Medicine
Date 2007 May 9
PMID 17485522
Citations 7
Authors
Hema Bashyam
Affiliations
Soon will be listed here.
Abstract

Early resistance to pathogens requires a swift response from NK cells. In 1989, Giorgio Trinchieri identified an NK growth factor and activator, later called interleukin-12 (IL-12). This discovery helped reveal the regulatory link between innate and adaptive immunity.

Citing Articles

Newcastle Disease Virus Virotherapy: Unveiling Oncolytic Efficacy and Immunomodulation.

Zaher K, Alrahimi J, Basingab F, Aldahlawi A Biomedicines. 2024; 12(7).

PMID: 39062070 PMC: 11274839. DOI: 10.3390/biomedicines12071497.

Host-functionalization of macrin nanoparticles to enable drug loading and control tumor-associated macrophage phenotype.

Sarkar B, Arlauckas S, Cuccarese M, Garris C, Weissleder R, Rodell C Front Immunol. 2024; 15:1331480.

PMID: 38545103 PMC: 10965546. DOI: 10.3389/fimmu.2024.1331480.

B-cell acute lymphoblastic leukemia promotes an immune suppressive microenvironment that can be overcome by IL-12.

Hunter R, Imbach K, Zhou C, Dougan J, Hamilton J, Chen K Sci Rep. 2022; 12(1):11870.

PMID: 35831470 PMC: 9279427. DOI: 10.1038/s41598-022-16152-z.

Intratumoral Plasmid IL12 Expands CD8 T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy.

Telli M, Nagata H, Wapnir I, Acharya C, Zablotsky K, Fox B Clin Cancer Res. 2021; 27(9):2481-2493.

PMID: 33593880 PMC: 8102331. DOI: 10.1158/1078-0432.CCR-20-3944.

Localized Interleukin-12 for Cancer Immunotherapy.

Nguyen K, Vrabel M, Mantooth S, Hopkins J, Wagner E, Gabaldon T Front Immunol. 2020; 11:575597.

PMID: 33178203 PMC: 7593768. DOI: 10.3389/fimmu.2020.575597.

References
1.
Kobayashi M, Fitz L, Ryan M, Hewick R, Clark S, Chan S . Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 1989; 170(3):827-45. PMC: 2189443. DOI: 10.1084/jem.170.3.827. View
2.
Perussia B, Ramoni C, Anegon I, Cuturi M, Faust J, Trinchieri G . Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines. Nat Immun Cell Growth Regul. 1987; 6(4):171-88. View
3.
Trinchieri G . Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003; 3(2):133-46. DOI: 10.1038/nri1001. View
4.
Trinchieri G, Kobayashi M, Rosen M, Loudon R, Murphy M, Perussia B . Tumor necrosis factor and lymphotoxin induce differentiation of human myeloid cell lines in synergy with immune interferon. J Exp Med. 1986; 164(4):1206-25. PMC: 2188407. DOI: 10.1084/jem.164.4.1206. View
5.
Degliantoni G, Murphy M, Kobayashi M, Francis M, Perussia B, Trinchieri G . Natural killer (NK) cell-derived hematopoietic colony-inhibiting activity and NK cytotoxic factor. Relationship with tumor necrosis factor and synergism with immune interferon. J Exp Med. 1985; 162(5):1512-30. PMC: 2187923. DOI: 10.1084/jem.162.5.1512. View